Biotechnology

Monday Mar 29, 2021 - 11:53 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in NetworkNewsAudio Broadcast

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, this morning announced that it was featured in a NetworkNewsAudio production highlighting the company’s recent news that it has received European approval for its SARS-CoV-2 (COVID-19) RT-PCR test system (Covid-ID Lab). “Our test is one of the fastest PCR-based COVID-19 tests…

Friday Mar 26, 2021 - 12:13 pm

InvestorNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Breakthrough Technology Rectifies Cystoscopy Limitations

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed proprietary technology that solves the issues associated with existing cystoscopies. “White light images show the full landscape of the bladder but do not effectively highlight cancer,” reads an article about the benefits of the i/Blue Imaging(TM) System, Imagin Medical’s proprietary technology. “A promising new modality, blue light cystoscopy, uses blue-filtered white light to…

Friday Mar 26, 2021 - 10:00 am

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases FY 2020 Financial, Corporate Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial numbers for the year ending Dec. 31, 2020; the company also reported a corporate update. High on the list of noteworthy achievements for the year 2020 was the selection of five U.S. clinical sites for the…

Friday Mar 26, 2021 - 9:26 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY 2020 Financial, Operational Results

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), reported is financial and operational results for the fourth quarter and fiscal year ending Dec. 31, 2020. The company also held a conference call on March 25, 2021, to discuss the new report. High on the list of significant…

Thursday Mar 25, 2021 - 1:29 pm

InvestorNewsBreaks – Kaival Brands Innovations Group Inc. (KAVL), Bidi Welcome Category Reform in China

Kaival Brands Innovations Group (KAVL), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, has noted recent news from China outlining increased supervision over the e-cigarette category. KAVL, which is the exclusive global distributor of all products manufactured by Bidi Vapor LLC, welcomes the news, particularly as it pertains the BIDI(R) Stick disposable electronic nicotine delivery system (“ENDS”). The company…

Thursday Mar 25, 2021 - 1:14 pm

InvestorNewsBreaks – Healthy Extracts Inc. (HYEX) Achieves Strong Growth Amid Booming Market

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of heart health, brain health and supplementary technologies, reported a revenue increase of 71% from $748,377 in 2019 to $1,276,559 over the 12 months ending December 31, 2020. The company attributes this growth to the transition to its new business selling health nutrition products, which positions HYEX for opportunity in the booming plant-based foods and products…

Wednesday Mar 24, 2021 - 1:17 pm

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Working to Expand Test Portfolio

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which recently received European approval for its COVID-19 rapid and portable test system, has set out to increase its portfolio of tests for different diseases to help fight the current and potential pandemics. XPhyto has partnered with Germany’s 3a-diagnostics GmbH for this, according to an article on the company’s recent announcements. “The company is also working with…

Wednesday Mar 24, 2021 - 12:58 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Spring 2021 Oncology Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will present at the Spring 2021 Oncology Investor Conference taking place virtually March 29 - April 2, 2021. According to the update, Genprex’s president and CEO, Rodney Varner, will deliver a virtual company overview that includes GNPX’s novel gene therapies for non-small…

Tuesday Mar 23, 2021 - 11:21 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Biotech Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced that it will participate at the Benzinga Biotech Small Cap Conference taking place from March 24-25, 2021. Vivos Chief Executive Officer, Kirk Huntsman, Chief Financial Officer, Brad Amman, and Investor Relations Officer, Ed Loew, will be…

Tuesday Mar 23, 2021 - 11:00 am

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Appoints Board Chair as New CEO

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announce the appointment of a new CEO: J. Melville (“Mel”) Engle. Engle is currently serving as chairman of the board and will continue to serve in that role as well as in his new position as CEO. Engle has more than two decades of impressive experience…

Monday Mar 22, 2021 - 10:08 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Phase 2 MS1819-PERT Combination Clinical Trial

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced completion of enrollment in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (“PERT”). The combination trial is for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”).…

Friday Mar 19, 2021 - 3:37 pm

InvestorNewsBreaks – RYAH Group Inc. Provides Digital Approach to Positively Impact Future Medical Treatments

RYAH Group, a leading digital health care analytics and technology company, has developed a technology that collects and analyzes patient data, creating an anonymous database that, when coupled with AI, will guide the future of medical treatments. With the technology, “patients can set usage limits, track usage in real time, record how they feel after sessions and review stats over time,” reads an article on…

Friday Mar 19, 2021 - 11:59 am

InvestorNewsBreaks – Bio-Path Holdings Inc. (NASDAQ: BPTH) Secures $13M in Public Offering

Bio-Path Holdings (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize(R) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, has closed a public offering of 1,710,600 shares of common stock. Bio-Path Holdings secured approximately $13 million in gross proceeds, with each of the shares sold at the public offering price of $7.60. Bio-Path intends to use the proceeds…

Wednesday Mar 17, 2021 - 1:24 pm

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Sites for Phase 2B Clinical Trial

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announced that it has selected five U.S. clinical sites to enroll patients with ulcerative necrobiosis lipoidica for the company’s Phase 2B trial. In addition, two to three more clinical sites will be selected…

Wednesday Mar 17, 2021 - 9:33 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Enters Strategic Collaboration with JelikaLite

Brain Scientific (OTCQB: BRSF), a neurology focused medical device and software company, recently announced a collaboration with JelikaLite, a company developing Cognilum(TM), a non-invasive wearable photobiomodulation device that is being developed to increase the well-being of children living with autism, through a clinical trial. In the trial, “Transcranial Photobiomodulation for Reducing Autism Symptoms in Children,” brain treatments for children diagnosed with autism would be delivered…

Tuesday Mar 16, 2021 - 1:38 pm

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Upcoming Phase 2b Clinical Trial of Cystic Fibrosis Treatment

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has announced the completion of enrollment for its phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis (“CF”) patients with exocrine pancreatic insufficiency (“EPI”). According to the announcement, the company enrolled 30 CF patients for the study, which is anticipated to return…

Tuesday Mar 16, 2021 - 12:46 pm

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Announces Continued Manufacturing Progress

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Prior to selection of Lighthouse as its contract manufacturer for the i/Blue Imaging System(TM) in October 2020, Imagin received multiple fully functional feasibility units from its original design partner,…

Tuesday Mar 16, 2021 - 12:21 pm

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming March Investor Conferences

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in two investor conferences in March. For the Maxim Group and M-Vest’s Inaugural Emerging Growth Virtual Conference taking place on March 17-19, 2021,…

Tuesday Mar 16, 2021 - 9:48 am

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Releases FY 2020 Financial Results, Business Highlights

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has reported business highlights and financial results for the year ended Dec. 31, 2020. Highlights discussed in the report include the company’s reinforced balance sheet with net debt and equity offerings for estimated net proceeds of $12,952,689; completion of an asset purchase agreement to acquire Soluble…

Thursday Mar 11, 2021 - 11:29 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Leaders to Present at Upcoming Virtual Investor Summit

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”) has announced that CEO Kirk Huntsman, CFO Brad Amman and investor relations officer Ed Loew are scheduled to present at the Q1 Virtual Investor Summit. Vivos Therapeutics’ presentation is scheduled for 1:30 p.m. ET on March 23, 2021. The…

Wednesday Mar 10, 2021 - 9:59 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announced Partner Has Received ISO Certification for Rapid COVID-19 Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has announced that 3a-diagnostics GmbH ("3a") has received EN ISO 13485 certification for its rapid point-of-care, SARS-CoV-2 RT-PCR Test System ("Covid-ID Lab"). 3a-diagnostics is XPhyto’s exclusive German diagnostics development partner. In addition the company expects CE-IVD approval for the product this month. These…

Wednesday Mar 10, 2021 - 9:02 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces FDA 510(k) Application for Exclusive Oral Appliance

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), recently submitted an application to the U.S. Food and Drug Administration (“FDA”) for its mmRNA (“mmRNA”) oral appliance(TM). The 510(k) Class II application focuses on the oral appliance as a treatment for mild-to-moderate OSA, sleep-disordered breathing and snoring in…

Tuesday Mar 09, 2021 - 12:46 pm

InvestorNewsBreaks – Healthy Extracts Inc. (HYEX) Releases FY 2020 Revenue Results, Year-End Accomplishments

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of heart health, brain health and supplementary technologies, has announced its year-end financial numbers and business updates for the 12-month period ending Dec. 31, 2020. Financial highlights of the report include revenue increases of 71% to $1,276,559 compared to 2019 revenues of $748,377 and a net shareholder equity increase of $3.7 million. In addition, the company eliminated…

Tuesday Mar 09, 2021 - 11:53 am

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Reports Q4, FY 2020 Numbers, Business Highlights

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has released its financial and business update report for the fourth quarter and full year 2020. The company reports significant progress across all aspects of its long-term strategic operating plan, including securing several accounts in the B2B (“B2B”) channel that are generating revenue and enrolling members and completing financing that provides capital to move…

Tuesday Mar 09, 2021 - 11:01 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Secures FDA Clearance for Next-Gen NeuroCap(TM)

Brain Scientific (OTCQB: BRSF), a neurology focused medical device and software company, today announced its receipt of U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its next-generation NeuroCap(TM) device. NeuroCap is an advanced electroencephalogram (“EEG”) electrode array used to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired. “We are constantly working on new products for the…

Monday Mar 08, 2021 - 1:54 pm

InvestorNewsBreaks – GT Biopharma Inc. (NASDAQ: GTBP) Releases Preclinical Results for Prostate Cancer Treatment

GT Biopharma (NASDAQ: GTBP), a clinical-stage biopharmaceutical company focused on disruptive, target-directed natural killer (“NK”) cell engager immunotherapy technologies, has announced preclinical results for its ROR1 (“ROR1”) TriKE(TM) (“TriKE”) product candidate, which is being evaluated as a prospective therapy for the treatment of prostate cancer. The treatment is based on the fact that tyrosine kinase transmembrane receptor ROR1 has been shown to be overexpressed on…

Monday Mar 08, 2021 - 1:47 pm

InvestorNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Develops First-Ever Effective Treatment for Root-Rot Disease

MustGrow (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) has announced that its plant-based biopesticide is 100% effective against root-rot disease. This announcement followed a recent round of laboratory tests, “which were conducted by an independent third-party lab,” an article on MustGrow’s novel accomplishment details. MustGrow, an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, becomes the…

Monday Mar 08, 2021 - 1:25 pm

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Opens First-Ever Pneusomnia Clinic, Unveils New Tech to Test for Sleep Apnea at Home

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has opened the first Pneusomnia clinic, a clinician-owned, integrated medical-dental sleep center. The center will feature the Vivos System through its Medical Integration Division. Located in Del Mar, California, the clinic is owned and operated by local physicians, including Dr. Mimi Guarneri,…

Monday Mar 08, 2021 - 12:24 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Development of Newly Designed System for Direct-to-Drain Fluid Waste Management

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Skyline Medical Division is renewing the development of a new Generation 3 STREAMWAY(R) System for direct-to-drain fluid waste management. According to the update the new device will see no change to its intended use and will not require a separate 501(k) submission…

Monday Mar 08, 2021 - 11:16 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Plans to Participate in 33rd Annual ROTH Conference, $10M Registered Direct Offering

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that its CEO and Chairman, James Sapirstein, will participate in a panel discussion during the ROTH Conference slated to be held virtually from March 15-17, 2021. According to the update, the panel, “Therapeutics Against SARS-CoV-2 – Viral Variants Will Not Fade Away: A discussion of various…

Friday Mar 05, 2021 - 2:03 pm

InvestorNewsBreaks – United Medical Equipment Business Solutions Network Inc. Offers Hi-Fi Masks, Other Essentials Amid Pandemic

United Medical Equipment (“UME,” “UMEBSNI”) is the distributor of a comprehensive line of COVID-19 products, including high-filtration (“hi-fi”) masks, the most effective in protecting against the pandemic. According to a recent article, the company offers a separate product line dedicated entirely to the needs of patients and health-care providers whose lives and work are impacted by the COVID-19 pandemic. This includes a wide range hi-fi…

Friday Mar 05, 2021 - 1:51 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Solution Holds Ability to Bridge the Gap in Neuro Testing

Brain Scientific (OTCQB: BRSF) is focused on modernizing brain diagnostics through cutting-edge technologies. The company’s NeuroCap(TM) offers a cost-effective, disposable solution that has the ability to bridge the gap in access to neurological testing. A recent article discussing this reads, “The NeuroCap has clear advantages to its bulkier EEG counterpart. The bulkier version requires a skilled specialist to administer, comes with metal disks and wires,…

Friday Mar 05, 2021 - 1:37 pm

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Bringing Effective Solutions to Vast Market

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is engaged in establishing a new standard for the visualization of cancer during minimally invasive surgeries (“MIS”). The company is currently focused on bladder cancer, the most expensive cancer to treat due to a high 50% recurrence rate that leaves approximately 600,000 U.S. patients living in fear that their cancer will return. Imagin Medical’s i/Blue(TM)…

Thursday Mar 04, 2021 - 2:26 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leveraging AI, Proprietary Database to Improve Outcomes for Patients of Today and Tomorrow

Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has been a forerunner in the field, helping oncologists individualize cancer treatment through its Helomics division. A recent article discussing this reads, “Predictive Oncology is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment…

Thursday Mar 04, 2021 - 2:12 pm

InvestorNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Pipeline Holds Potential to Go Beyond Standard of Care for Anxiety, Depression

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications that go beyond the standard of care for anxiety and depression. A recent article discussing this reads, “Depression and anxiety are at the forefront of concern for VistaGen, a company working to develop innovative product candidates to address these substantial issues. For example, FDA-approved oral antidepressants are slow to…

Wednesday Mar 03, 2021 - 2:32 pm

InvestorNewsBreaks – RYAH Group Inc. Set to be at Forefront of Data-Driven Medical Future

RYAH Group, a leading digital health care analytics and technology company, is set to benefit with a commitment to advancing the world’s transition to remote-health solutions and data analytics in patient treatments. A recent Becker’s Hospital Review article cites 10 emerging trends in health IT that will shape the field in 2021, reporting that big data management is increasingly necessary with the blossoming use of…

Wednesday Mar 03, 2021 - 10:37 am

InvestorNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Isolates and Concentrates a Mustard-Derived Molecule that Acts as a Systemic, Non-Selective Bioherbicide

MustGrow (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, today announced that it has isolated and concentrated an additional molecule, thiocyanate, from mustard seed. According to the update, thiocyanate is responsible for the systemic activity behind the mustard plant's natural herbicidal (weed-killer) properties and is the third molecule from mustard seed that MustGrow…

Tuesday Mar 02, 2021 - 1:45 pm

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes $10.2M Private Placement

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has closed its previously announced private placement to institutional and accredited investors. According to the update, the company sold 1,321,132 shares of its common stock at a purchase price of $7.75 per share for $10.2 million in the private placement.…

Tuesday Mar 02, 2021 - 12:59 pm

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Releases Results of New Clinical Study Showing Value of Personalization

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has announced the results of a new clinical study that examined the connection between personalization and sustained behavior change in digital health. The study indicates increased digital engagement resulted in 43% improvement in blood glucose levels. The study results were compiled in a paper titled "Role of Digital Engagement in Diabetes Care Beyond Measurement:…

Tuesday Mar 02, 2021 - 11:25 am

InvestorNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Secures $3.6M from Exercised Warrants

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced its receipt of approximately CA$3.6M (US$2.9M) in warrant exercises since the start of 2021. “Achieving our first commercial sales in combination with a very positive outlook for 2021 has resulted in the appreciation of our share price over the last few months,” said Dr. Jack…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions